Genetic Technologies to Hold Investor Webinar and Q&A Session on November 19
November 17 2020 - 08:30AM
Molecular diagnostics company Genetic Technologies Limited (ASX:
GTG; Nasdaq: GENE, “Company”) is pleased to announce its
interim-CEO, Dr. Jerzy Muchnicki, will share insight into the
company’s recent developments during an investor webinar on
Thursday, November 19, 2020 at 4:15 p.m. ET. A live Q&A session
with Dr. Muchnicki will follow the presentation.
To participate in the webinar, please register
at: https://www.redchip.com/corporate/webinar_register/78
Questions can be pre-submitted to
victor@redchip.com or on the website during the event.
About Genetic Technologies
Limited
Genetic Technologies Limited is a diversified
molecular diagnostics company. GTG offers cancer predictive testing
and assessment tools to help physicians proactively manage patient
health. The Company's lead products GeneType for Breast Cancer for
non-hereditary breast cancer and GeneType for Colorectal Cancer are
clinically validated risk assessment tests and are first in class.
Genetic Technologies is developing a pipeline of risk assessment
products.
For more information, please
visit www.gtglabs.com
Cautionary Note Regarding
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements,” within the meaning of
federal securities laws, including statements related to the
Company’s anticipated use of proceeds and plans and prospects and
other statements containing the words “anticipate,” “intend,”
“may,” “plan,” “predict,” “will,” “would,” “could,” “should,” and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. The Company's actual results could differ materially from
those anticipated in these forward-looking statements as a result
of various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the known risks, uncertainties
and other factors described in the Company’s prior filings and from
time to time in the Company’s subsequent filings with the
Securities and Exchange Commission. Any change in such factors,
risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such
statements. All information in this press release is as of the date
of the release and the Company does not undertake any duty to
update this information, including any forward-looking statements,
unless required by law.
FOR FURTHER INFORMATION PLEASE CONTACT
Investor Relations and Media
(US)Dave Gentry, CEORedChip CompaniesOffice: 1 800 RED
CHIP (733 2447)Cell: US 407 491 4498dave@redchip.com
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Mar 2023 to Mar 2024